Phibro Animal Health (PAHC) Total Current Liabilities (2013 - 2026)
Phibro Animal Health's (PAHC) quarterly Total Current Liabilities came in at $281.9 million in Q1 2026, up 5.77% year-on-year from $266.5 million in Q1 2025, and little changed quarter-over-quarter from $282.4 million in Q4 2025.
Phibro Animal Health (PAHC) Total Current Liabilities (2013 - 2026) Analysis & Trends
Phibro Animal Health's Total Current Liabilities history runs 14 years deep, the most recent figure standing at $281.9 million for Q1 2026.
- On a quarterly basis, Total Current Liabilities rose 5.77% year-over-year to $281.9 million in Q1 2026; TTM through Mar 2026 was $281.9 million, a 5.77% increase from a year earlier, with the FY2025 full-year figure at $293.5 million, up 43.76% from the prior year.
- Total Current Liabilities held at $281.9 million in Q1 2026 per PAHC's latest filing, from $282.4 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $293.5 million in Q2 2025 and bottomed at $165.3 million in Q1 2023.
- The 5-year median for Total Current Liabilities is $189.1 million (2024), against an average of $212.8 million.
- Across the five-year window, Total Current Liabilities retreated 11.65% in 2023 and jumped 52.71% in 2025, its largest moves.
- Year by year, Total Current Liabilities stood at $167.6 million in 2022, then climbed by 12.03% to $187.7 million in 2023, then increased by 24.24% to $233.2 million in 2024, then rose by 21.06% to $282.4 million in 2025, then slipped by 0.18% to $281.9 million in 2026.
- Per Business Quant, the three latest PAHC Total Current Liabilities figures stand at $281.9 million (Q1 2026), $282.4 million (Q4 2025), and $270.1 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 6.56 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 13.53 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 2.05 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 18.06 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 599.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 13.17 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 6.81 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 831.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 1.66 Bn |
| 10 | Phibro Animal Health | 1.38 Bn | 1.30 Bn | 125.68 Mn | 281.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 281.87 Mn |
| Dec 31, 2025 | 282.37 Mn |
| Sep 30, 2025 | 270.14 Mn |
| Jun 30, 2025 | 293.47 Mn |
| Mar 31, 2025 | 266.48 Mn |
| Dec 31, 2024 | 233.25 Mn |
| Sep 30, 2024 | 176.89 Mn |
| Jun 30, 2024 | 204.15 Mn |
| Mar 31, 2024 | 189.07 Mn |
| Dec 31, 2023 | 187.74 Mn |
| Sep 30, 2023 | 172.36 Mn |
| Jun 30, 2023 | 176.00 Mn |
| Mar 31, 2023 | 165.31 Mn |
| Dec 31, 2022 | 167.57 Mn |
| Sep 30, 2022 | 172.50 Mn |
| Jun 30, 2022 | 190.83 Mn |
| Mar 31, 2022 | 187.10 Mn |
| Dec 31, 2021 | 166.63 Mn |
| Sep 30, 2021 | 152.59 Mn |
| Jun 30, 2021 | 164.12 Mn |